Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-10-24 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
第六届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results on various proposals including approval of the 2024 Q3 report, appointment of a deputy general manager, approval of a loan application by a subsidiary, and the proposal to convene an extraordinary general meeting. The document is a board meeting resolution announcement rather than the actual quarterly report or financial statements. It also references other announcements and reports published separately on the stock exchange platform. The content focuses on board decisions and management appointments, which aligns with the category of Board/Management Information (MANG). The document length is short (2290 characters), and it does not contain substantive financial data or the full report itself, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the correct classification is MANG with high confidence.
2024-10-24 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司向控股子公司提供担保事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中泰证券股份有限公司) regarding a guarantee provided by Beijing Nuosiland Biotechnology Co., Ltd. to its controlling subsidiary. It details the guarantee arrangements, approval procedures, and the sponsor's opinion on the matter. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement about a financing guarantee and related approvals, not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about corporate guarantees and approvals.
2024-10-24 Chinese
关于控股子公司申请银行贷款暨公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a bank loan application by a controlling subsidiary and the parent company's provision of guarantees. It details the loan amount, collateral, board approval, and regulatory compliance. The document is a formal disclosure of a financing-related event, specifically about a loan and guarantee arrangement, but it does not contain financial statements or detailed financial performance data. It is not a full financial report, audit report, or earnings release. It is not a simple announcement of a report publication either. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities and capital structure changes.
2024-10-24 Chinese
副总经理任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new deputy general manager (副总经理) at Beijing Northland Biotechnology Co., Ltd. It details the board meeting resolution, voting results, the appointee's background, and compliance with company law and governance rules. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-10-24 Chinese
关于召开2024年第一次临时股东大会通知公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会) for Beijing Northland Biotechnology Co., Ltd. It details the meeting date, voting methods, attendees, agenda items, and registration procedures. It does not contain financial statements or results but is an announcement about the meeting itself. The document length is 2341 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-10-24 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of Beijing Northland Biotechnology Co., Ltd. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial data changes. The report covers the period ending September 30, 2024, and includes comprehensive financial metrics, shareholder information, and management assurances about the report's accuracy. The length is substantial (15,000 characters), and it contains actual financial statements and analysis for a period shorter than a full fiscal year (quarterly). It explicitly states it is a quarterly report and is unaudited. This matches the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.